logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Eribulin fails phase 2 trial of residual invasive early breast cancer

2-year DFS among 3 subtypes of residual invasive breast cancer failed to exceed projected expectations.